曲格列酮在人前列腺癌细胞中对核受体结合蛋白1表达调控的影响  

Effect of troglitazone on NRBP1 expression in prostate cancer cell

作　　者：杜晚林 杜媛 李克勤[3] 陈江平[3] 张仕强 陈燕 

机构地区：[1]岳池红十字川东医院,四川岳池638300 [2]苏州虎丘医院,江苏苏州215008 [3]岳池县人民医院,四川岳池638300 [4]岳池县疾病预防控制中心,四川岳池638300

出　　处：《现代医药卫生》2012年第18期2726-2727,2730,共3页Journal of Modern Medicine & Health

基　　金：国家自然科学基金资助项目(30901593)

摘　　要：目的探讨在人前列腺癌株DU145细胞中过氧化物酶体增殖活化受体γ(PPARγ)的特异性激动剂曲格列酮对核受体结合蛋白1(NRBP1)的表达调控作用。方法 MTT法检测不同浓度曲格列酮(浓度分别为0.5、5.0、10.0μmol/L)作用24 h后对DU145细胞增殖的影响。在DU145细胞中用PPARγ的特异性激动剂曲格列酮处理24 h后,在转录水平和翻译水平检测NRBP1的表达。结果曲格列酮各浓度实验组对细胞的活性和增殖无影响(P>0.05)。曲格列酮作用于DU145细胞后在转录水平和翻译水平对NRBP1有明显抑制作用。结论 PPARγ在DU145细胞中可抑制NRBP1的表达。Objective To investigate the effect of the specific agonist troglitazone of peroxisome proliferator-activated receptor γ（PPARγ） on the expression of nuclear receptor binding protein 1（NRBP1） in DU145 cells.Methods The effect of various troglitazone concentrations on the viability of DU145 cells was detected by MTT test.Human prostate cancer cells were treated with PPARγ specific agonist troglitazone and then NRBP1 mRNA and protein were assayed by using RT-PCR and Western blot.Results Troglitazone had no effect on the viability of DU145 cells（P〉0.05）.After treatment by troglitazone with different concentrations in DU145 cells,NRBP1 was downregulated in both mRNA and protein.Conclusion PPARγ could inhibit the expression of NRBP1 in DU145 cells.

关 键 词：受体 胞质和核 前列腺肿瘤 肿瘤细胞 培养的 降血糖药 曲格列酮 

分 类 号：R737.25[医药卫生—肿瘤]